Table 3.
Combination | Duration | Comments | |
---|---|---|---|
Pulmonary | |||
Cavitary disease Pneumonia |
Clarithromycin 500–1000 mg/d or Azithromycin 250–300 mg/d Rifampicin 450–600 mg/d |
Up to 12 months, negative culture Initial administration of injectable agents for 8 to 12 weeks Streptomycin (10–15 mg/kg/3x/week) Amikacin 8–25 mg/kg 2-3 times weekly |
In case of macrolide resistance or intolerance clofazimine and quinolones may be useful based on strain resistance profiles |
Bronchiectatic-fibronodular CF, COPD |
Clarithromycin 1000 mg/d or Azithromycin 500–600 mg/d Ethambutol 25 mg/kg Rifampicin 600 mg |
Intermittent three times weekly In nonresponsive output change to daily dosage |
Adjuvant therapy of underlying disease, bronchodilators, airways clearance support, smoking cessation, and nutrition |
Hypersensitivity | Prednisone 1-2 mg/kg/daily | 4–8 weeks, repeated exposure must be avoided | Long postexposure observation to exclude lung disease progression |
| |||
Extrapulmonary | |||
Systemic, disseminated, and HIV infection | Clarithromycin 500 mg/twice daily or Azithromycin 1200 mg/daily Rifabutin 300 mg/d Ethambutol 15 mg/kg daily |
Up to 12 months Initial administration of injectable agents for 8 to 12 weeks Streptomycin (10–15 mg/kg/3x/week) Amikacin 8–25 mg/kg 2-3 times weekly |
Prevention Azithromycin 500 mg/daily Ethambutol 15 mg/kg daily or Clarithromycin 500 mg/twice daily +/− Rifabutin 300 mg/daily, HIV with < 50 CD4 cells/L |
Skin, soft tissue, and osteoarticular disease | Chirurgical debridement, excision Support: Clarithromycin 500–1000 mg/d or Azithromycin 250–300 mg/d Rifampicin 450–600 mg/d |
In case of indolent persistence, supportive in more excessive involvement: Streptomycin (10–15 mg/kg/3x/week) Amikacin 8–25 mg/kg 2-3 times weekly |
|
Lymphadenitis |
Complete extirpation
Support: Clarithromycin Rifampicin |
Duration and dosage not established,see pulmonary, consider Ethambutol with caution in infants! | Antibiotic treatment only in cases where extirpation is contraindicated or with poor outcome after surgery, considering superinfection with other microorganisms |